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20(S)-protopanaxatriol (PPT) is an aglycone of ginsenosides isolated from Panax ginseng and has several
interesting activities, including anti-inﬂammatory and anti-oxidative stress effects. Herein, PPT was
identiﬁed as an inhibitor against the ligand-dependent transactivation of liver X receptor a (LXRa) using
a Gal4-TK-luciferase reporter system. LXRa is a transcription factor of nuclear hormone receptor family
and stimulates the transcription of many metabolic genes, such as lipogenesis- or reverse cholesterol
transport (RCT)-related genes. Quantitative RT-PCR analysis showed that PPT inhibited the LXRa-
dependent transcription of lipogenic genes, such as sterol regulatory element binding protein-1c (SREBP-
1c), fatty acid synthase, and stearoyl CoA desaturase 1. These inhibitory effects of PPT are, at least in part,
a consequence of the reduced recruitment of RNA polymerase II to the LXR response element (LXRE) of
the SREBP-1c promoter. Furthermore, LXRa-dependent triglyceride accumulation in primary mouse
hepatocytes was signiﬁcantly reduced by PPT. Interestingly, PPT did not inhibit the LXRa-dependent
transcription of ABCA1, a crucial LXRa target gene involved in RCT. Chromatin immunoprecipitation
assays revealed that PPT repressed recruitment of the lipogenic coactivator TRAP80 to the SREBP-1c
LXRE, but not the ABCA1 LXRE. Overall, these data suggest that PPT has selective inhibitory activity
against LXRa-mediated lipogenesis, but not LXRa-stimulated RCT.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Liver X receptor a (LXRa) is a transcription factor of nuclear
receptor superfamily and regulates the expression of many lipo-
genic genes, including sterol regulatory element binding protein-1c
(SREBP-1c), fatty acid synthase (FAS), and stearoyl CoA desaturase 1
(SCD1) (1e5). Because of the increased expression of these genes,
treatment of mice with LXR agonists, such as T0901317 or GW3965,
can induce a fatty liver. Moreover, SREBP-1c, one of the LXRa target
genes, is a transcription factor of the basic-helix-loop-helix-leucine
zipper family and is known to be a master regulator of the lipogenic
pathway (6). Therefore, LXRa is considered to be a crucial target for
the development of anti-lipogenic agents. On the other hand, LXRa
also stimulates the expression of reverse cholesterol transportology, Asan Medical Center,
, Republic of Korea. Tel.: þ82
.
rmacological Society.
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d/4.0/).(RCT)-related genes, such as ATP-binding cassette transporter A1
(ABCA1) and G1 (ABCG1), which contribute to the increase of
HDL-cholesterol levels and are beneﬁcial for the treatment of
atherosclerosis (7, 8).
For more than 2000 years, the root of Panax ginseng C. A. Meyer
(Family Araliaceae) has been used as a panacea because of its tonic
functions. For metabolic diseases, ginseng and its constituent gin-
senosides have been shown to exert therapeutic effects in several
diseasemodels of diabetesmellitus and obesity (9e16), as well as in
diabetic patients (17). However, the speciﬁc active constituents and
their underlying action mechanisms remain largely unknown.
Ginsenosides are a special group of triterpenoid saponins found
exclusively in ginseng and can be classiﬁed based on their agly-
cones (nonsugar components) into two groups: 20(S)-proto-
panaxadiol (PPD)-type and 20(S)-protopanaxatriol (PPT)-type
ginsenosides. The ginsenosides Rb1, Rb2, Rc, Rd, and Rh2 are the
PPD-type ginsenosides, while the PPT-type ginsenosides include
Re, Rf, Rg1, Rg2, and Rh1. Both the PPD- and PPT-type ginsenosides
can be deglycosylated by gastric acid and/or intestinal bacteria,nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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aglycones.
In our current study, the aglycone PPT was identiﬁed as an
inhibitor of autonomous LXRa transactivation using a Gal4-UAS
screening system. Previous studies by other researchers have
revealed several interesting activities of PPT. Oh et al. reported that
PPT reduces the expression levels of inducible nitric oxide synthase
and cyclooxygenase-2 through the inactivation of NFkB by pre-
venting IkBa phosphorylation in RAW 264.7 macrophages stimu-
latedwith lipopolysaccharide (18). Kwok et al. have shown that PPT
protects endothelial cells from hydrogen peroxide-induced cell
death (19). Han et al. reported that PPT increases the trans-
activation activity of peroxisome proliferator-activated receptor g
(PPARg) in a dose-dependent manner and enhances adipogenesis
by increasing the expression of PPARg target genes, such as fatty
acid binding protein 4, lipoprotein lipase, and phosphoenolpyr-
uvate carboxykinase (20). However, no study has yet examined the
effect of PPT on LXRa-mediated lipogenesis.
Our present study aimed to identify an anti-lipogenic compound
based on the inhibition of LXRa transactivation and to further
investigate the mechanism of action of such a compound at the
transcriptional level. Our data show that PPT is a novel LXRa
inhibitor with selective effects on lipogenic process. Interestingly,
PPT did not inhibit the transcription of LXRa target gene related to
RCT process. We suggest a possible mechanism for the differential
inhibition of the lipogenesis and RCT pathways by PPT.
2. Materials and methods
2.1. Reagents and antibodies
Phytochemicals, including PPT, were provided by Dr. Won Keun
Oh (Korea Bioactive Natural Material Bank, Seoul National Univer-
sity, Seoul, Korea). T0901317 and dimethyl sulfoxide (DMSO) were
purchased from SigmaeAldrich (St. Louis, MO, USA). Percoll was
obtained from GE Healthcare (Pittsburgh, PA, USA). M199 medium
was from Gibco (Grand Island, NY, USA). Dulbecco's Modiﬁed Ea-
gle's Medium (DMEM) and fetal bovine serum (FBS) were obtained
from Hyclone (Logan, UT, USA). The primers used for PCR were
synthesized by Genotech (Daejeon, Korea). Rabbit anti-RNA poly-
merase II (sc-900X) and goat anti-TRAP80 (sc-12453) antibodies
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Rabbit anti-IgG control was purchased from Abcam
(Cambridge, UK).
2.2. Isolation of mouse primary hepatocytes and cell culture
Mouse primary hepatocytes were isolated from 8 to 10-week-
old male C57BL/6 mice (Orient Bio, Seongnam, Korea) using a
previously described collagenase perfusion method with minor
modiﬁcations (21). Brieﬂy, livers were perfused with Mg2þ/Ca2þ-
free Hanks' balanced salt solution (SigmaeAldrich) containing
100 U/mL collagenase type II (Gibco) and 48 mg/mL trypsin inhibitor
(SigmaeAldrich). Next, viable hepatocytes were collected using
Percoll density gradient centrifugation after ﬁltering liver cells
through a 100-mm nylon mesh strainer (BD Biosciences, San Jose,
CA, USA). Isolated primary hepatocytes were plated onto collagen
type I-coated culture dishes and maintained in M199 media. Hu-
man hepatoma HepG2 cells were maintained in DMEM containing
10% FBS at 37 C in a humidiﬁed 5% CO2 incubator. All animal
protocols were approved by the Institutional Animal Care and Use
Committee (IACUC) of the Asan Institute for Life Sciences, Asan
Medical Center (Approval No. 2013e12-168). Mice were main-
tained in a temperature-controlled facility with a 12 h light/12 h
dark cycle and were provided ad libitum access towater and regularrodent chow diet. Following acclimatization for 1 week, mice were
humanely euthanized for the preparation of primary hepatocytes.
2.3. Transient transfection and luciferase reporter assays
HepG2 cells were seeded in 24-well plates 24 h prior to trans-
fection and were grown in DMEM supplemented with 10%
charcoal-stripped FBS. Transfections were performed with Gal4-
TK-luciferase, Gal4-hLXRa ligand binding domain (LBD), SREBP-1c
LXRE (LXR response element)-luciferase, or ABCA1 LXRE-
luciferase constructs using Lipofectamine 2000 reagent (Invi-
trogen, Grand Island, NY, USA) according to the manufacturer's
protocol. After 24 h, cells were treated with 1 mM T0901317 and
10 mg/mL phytochemicals for 18 h. Luciferase activity was then
measured using a Centro LB 960 luminometer (Berthold Technol-
ogy, Bad Wildbad, Germany), and enzyme activity values were
normalized to those of b-galactosidase. For normalization, pActin-
bgal plasmids were co-transfected into HepG2 cells along with the
plasmids containing promoter-luciferase reporter genes.
2.4. Analysis of transcript levels by conventional or quantitative
RT-PCR
Total RNAwas extracted from primary hepatocytes treated with
1 mM T0901317 and 10 mg/mL PPT using TRIzol-RNA Lysis Reagent
(Invitrogen) according to the manufacturer's instructions. Puriﬁed
RNA was reverse transcribed by M-MLV reverse transcriptase
(Promega, Madison, WI, USA). Next, speciﬁc mRNA levels were
measured by conventional or quantitative RT-PCR. The oligonu-
cleotide primers used for conventional RT-PCR were as follows:
SREBP-1c, 5ʹ-GGC GCA TGG ATT GCA CAT TT-3ʹ and 5ʹ-GCA GGC TGT
AGG ATG GTG A-3ʹ; and 18S rRNA, 5ʹ-CGT CCC CCA ACT TCT TAG
AG-3ʹ and 5ʹ-CAC CTA CGG AAA CCT TGT TAC-3ʹ. For conventional
RT-PCR, 18S rRNA was used as an internal control. Quantitative RT-
PCR analyses were performed on a LightCycler 480 system (Roche,
Basel, Switzerland). The following oligonucleotide primers were
used for quantitative RT-PCR: SREBP-1c, 5ʹ-CAG CCA TGG ATT GCA
CAT TTG-3ʹ and 5ʹ-GTC TTG GTT GTT GAT GAG CTG G-3ʹ; SCD1, 5ʹ-
AGC TCAGTC TCA CTC CTT CCC TTA-3ʹ and 5ʹ-CAG CCAGCC TCT TGA
CTA TTC C-3ʹ; FAS, 5ʹ-CTG CAG CTG TCA GTG TGA AGA AG-3ʹ and 5ʹ-
GCA GCA TTT TTA CCA GGT TGG T-3ʹ; Glycerol-3-phosphate acyl-
transferase (GPAT), 5ʹ-TCA TCC AGT ATG GCA TTC TCA CA-3ʹ and
5ʹ-GCA AGG CCA GGA CTG ACA TC-3ʹ; ABCA1, 5ʹ-GAC CCG TAC TCT
CGC AGG G-3ʹ and 5ʹ-CCT TGC CGG TAT TTT AGC AGG-3ʹ; and
ribosomal protein S29 (RPS29), 5ʹ-CGC AAA TAC GGG CTG AAC A-3ʹ
and 5ʹ-GCC TAT GTC CTT CGC GTA CTG-3ʹ. RPS29 was used as an
internal control for quantitative RT-PCR.
2.5. Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed in primary hepatocytes treated
with 1 mM T0901317 and 10 mg/mL PPT for 30 min, as described
previously, with minor modiﬁcations (22). Brieﬂy, cells were ﬁxed
with 1% formalin (SigmaeAldrich) for 20 min and then quenched
with 0.125 M glycine for 5 min at room temperature. Cells were
washed twice with cold PBS and lysed in SDS lysis buffer con-
taining 50 mM TriseHCl (pH 8.0), 10 mM EDTA, and 1% SDS.
Soluble chromatin was prepared by sonication (VCX-600
Sonicator, Sonics & Materials, Newton, CT, USA) and then was pre-
cleared using protein G-agarose beads (Santa Cruz Biotechnology).
Pre-cleared supernatants were then immunoprecipitated with
anti-RNA polymerase II (Santa Cruz Biotechnology), anti-TRAP80
(Santa Cruz Biotechnology), or IgG antibodies (Abcam) for
12 h at 4 C. The remaining DNA was extracted from the immu-
noprecipitate and analyzed by quantitative RT-PCR using the
Fig. 1. Effects of ginsenosides and their aglycones on (A) the autonomous trans-
activation of Gal4-LXRa LBD and (B) LXRa agonist-stimulated increases of SREBP-1c
transcript levels. (A) Gal4-LXRa LBD transactivity was measured in the presence of
1 mM T0901317 and 10 mg/mL ginsenosides or their aglycones using a Gal4-TK-lucif-
erase assay (n ¼ 6). (B) The effects of ginsenosides and their aglycones on T0901317-
stimulated SREBP-1c mRNA levels were determined in primary hepatocytes by
conventional RT-PCR (n ¼ 3). Band intensities were quantiﬁed with the ImageJ pro-
gram. Data are presented as means ± SD. T1317, T0901317; PPT, 20(S)-proto-
panaxatriol; Re, ginsenoside Re; Rg2, 20(S)-ginsenoside Rg2; Rh1, 20(R)-ginsenoside
Rh1; Rd, ginsenoside Rd; PPD, 20(S)-protopanaxadiol. *, P < 0.05 vs. without T1317; **,
P < 0.01 vs. without T1317; ***, P < 0.001 vs. without T1317; #, P < 0.05 vs. T1317 alone;
##, P < 0.01 vs. T1317 alone; ###, P < 0.001 vs. T1317 alone.
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for the ChIP assay were as follows: SREBP-1c LXRE region, 5ʹ-AGG
CTC TTT TCG GGG ATG G-3ʹ and 5ʹ-TGG GGT TAC TGG CGG TCA
C-3ʹ; and ABCA1 LXRE region, 5ʹ-GGG GAA AGA GGG AGA GAA
CAG-3ʹ and 5ʹ-GAA TTA CTG GTT TTT GCC GC-3ʹ. Immunoprecipi-
tated DNA levels were presented as fold enrichments normalized
to 10% input DNA levels.
2.6. Cellular triglyceride (TG) accumulation
Primary hepatocytes were seeded onto 60 mm collagen-coated
culture dishes and incubated overnight in M199 medium. After
treatment with 1 mM T0901317 and 10 mg/mL PPT for 24 h, cells
were washed twice with cold phosphate buffered saline (PBS) and
lysed in PBS containing 1% Triton X-100 for 30 min at 4 C. Lysates
were centrifuged at 10,000  g for 10 min at 4 C. Cellular lipids
were then extracted from the supernatant using the Bligh and Dyer
method (23). TG levels were measured using a TG assay kit (Asan
Pharmaceutical, Gyeonggi-do, Korea) and normalized to total pro-
tein levels.
2.7. Statistical analyses
Results are presented as means ± SD. Data were analyzed using
SPSS version 19 (SPSS/IBM, Chicago, IL, USA). Statistical analyses
were performed using one-way analysis of variance (ANOVA).
Bonferroni multiple comparison tests were conducted for post-hoc
analysis. Differences with P values <0.05 were considered to be
statistically signiﬁcant. All experiments were repeated at least
three times.
3. Results
3.1. PPT inhibits the autonomous transactivation of Gal4-LXRa LBD
and the T0901317-dependent transcription of SREBP-1c
A Gal4/UAS reporter assay was used to determine the effects
of ginsenosides and their aglycones (PPT and PPD) on the
transactivation of Gal4-LXRa LBD. Among many phytochemicals
of ginseng, PPT and 20(R)-ginsenoside Rh1 exerted marked in-
hibition of the T0901317-dependent transactivation of Gal4-LXRa
LBD (Fig. 1A). Because SREBP-1c is a master regulator of lipo-
genesis and is also a major LXRa target gene, we investigated
the effects of PPT and other ginsenosides on the T0901317-
dependent stimulation of SREBP-1c transcription to estimate
the anti-lipogenic activities of these compounds. Conventional
RT-PCR analysis showed that PPT markedly suppressed the
LXRa-dependent transcription of SREBP-1c (Fig. 1B). The inhibi-
tory effect of 20(R)-ginsenoside Rh1 on T0901317-dependent
transcription of SREBP-1c was not statistically signiﬁcant
(Fig. 1B).
3.2. PPT inhibits the T0901317-dependent transactivation of the
SREBP-1c promoter and the recruitment of RNA polymerase II to the
LXRE region of SREBP-1c
To elucidate the mechanism of transcriptional inhibition of
SREBP-1c by PPT, we examined the effect of PPT on the activity of
SREBP-1c LXRE luciferase (a luciferase reporter containing SREBP-
1c LXRE promoter region). Importantly, PPT suppressed the
T0901317-dependent stimulation of SREBP-1c LXRE luciferase
activity (Fig. 2A). The recruitment of RNA polymerase II to the
endogenous LXRE of the SREBP-1c gene was then assessed using a
ChIP assay. Interestingly, the T0901317-dependent recruitment of
RNA polymerase II to the LXRE region of the SREBP-1c promoterwas abrogated by PPT treatment (Fig. 2B). These results suggest that
PPT directly regulates the transcription of SREBP-1c by modulating
the recruitment of RNA polymerase II.3.3. PPT inhibits T0901317-dependent transcription of LXRa target
genes related to lipogenesis, and reduces T0901317-induced TG
accumulation in primary hepatocytes
Because both LXRa and SREBP-1c are transcription factors that
can stimulate the transcription of many lipogenic enzymes, we
tested whether PPT could inﬂuence the expression of other lipo-
genic genes, such as SCD1, FAS, and GPAT. SREBP-1c, SCD1, and FAS
are LXRa target genes, while SCD1, FAS, and GPAT are SREBP-1c
target genes. Quantitative RT-PCR analysis revealed that PPT sup-
pressed the T0901317-dependent transcription of SREBP-1c, SCD1,
FAS, and GPAT in primary mouse hepatocytes (Fig. 3A). The
T0901317-dependent inductions of lipogenic SREBP-1c and FAS
proteins were also decreased by PPT in primary mouse hepatocytes
(Fig. 3B). Subsequently, we investigated the effect of PPT on cellular
TG accumulation induced by T0901317 in primary hepatocytes.
Importantly, T0901317-induced TG accumulation in hepatocytes
was signiﬁcantly reduced by PPT treatment (Fig. 3C). Together,
these data indicate that the inhibitory activity of PPT against LXRa
transactivation can result in reduced expression of lipogenic genes
and ultimately the suppression of TG accumulation in hepatocytes.
Fig. 3. Effects of PPT on (A, B) T0901317-dependent increases of lipogenic gene transcript and protein levels and (C) cellular TG accumulation in mouse primary hepatocytes.
(A) T0901317-induced transcription of SREBP-1c, SCD1, FAS, and GPAT was determined in the presence or absence of PPT using qRT-PCR (n ¼ 4). (B) The effects of PPT on T0901317-
stimulated expression of lipogenic proteins were determined by immunoblot analysis. (C) TG accumulation in response to co-treatment with T0901317 and PPT. Intracellular TG
levels were measured enzymatically after treatment of primary hepatocytes with 1 mM T0901317 and 10 mg/mL PPT and normalized to total protein levels (n ¼ 4). Data are presented
as means ± SD. DMSO, dimethyl sulfoxide; T1317, T0901317. *, P < 0.05 vs. DMSO; **, P < 0.01 vs. DMSO; ***, P < 0.001 vs. DMSO; #, P < 0.05 vs. T1317; ##, P < 0.01 vs. T1317; ###,
P < 0.001 vs. T1317.
Fig. 2. Effects of PPT on (A) the transcriptional activity of the SREBP-1c promoter and (B) the T0901317-dependent recruitment of RNA polymerase II to the LXRE region of the
SREBP-1c gene. (A) LXRa-mediated transcriptional activity was determined using SREBP-1c LXRE-luciferase reporters in the presence of 1 mM T0901317 and 10 mg/mL PPT in
HepG2 cells (n ¼ 8). Luciferase activity was normalized to cotransfected b-galactosidase activity. (B) After treatment of primary hepatocytes with 1 mM T0901317 and 10 mg/mL
PPT, ChIP assays were performed using anti-RNA polymerase II or IgG antibodies (n ¼ 4). Immunoprecipitated LXRE-containing DNA levels were determined by qRT-PCR and
normalized to input DNA. Data are presented as means ± SD. DMSO, dimethyl sulfoxide; T1317, T0901317. **, P < 0.01 vs. DMSO; ***, P < 0.001 vs. DMSO; #, P < 0.05 vs. T1317;
###, P < 0.001 vs. T1317.
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target gene
LXRa regulates not only lipogenic genes, but also RCT-related
genes, such as ABCA1 (7, 24). Moreover, RCT is considered to be a
beneﬁcial process for maintaining high HDL-cholesterol levels,
while lipogenesis is thought to be potentially harmful. Therefore,we investigated the effect of PPT on ABCA1 transcription. Inter-
estingly, PPT did not inhibit the promoter activity of ABCA1 in a
luciferase reporter system (Fig. 4A). T0901317-dependent increases
in ABCA1 transcript and protein levels were not repressed by PPT
(Fig. 4: B and C). Furthermore, PPT did not affect the T0901317-
stimulated recruitment of RNA polymerase II to the ABCA1 LXRE
region (Fig. 4D). These data indicate that PPT differentially affects
Fig. 4. Effects of PPT on (A) the LXRa-mediated promoter activity of ABCA1-Luc, (B) the mRNA transcript levels of ABCA1, (C) the protein levels of ABCA1 and (D) the recruitment of
RNA polymerase II to the LXRE region of the ABCA1 gene. (A) The activity of ABCA1 LXRE-luciferase was determined, following treatment with 1 mM T0901317 and 10 mg/mL PPT, in
HepG2 cells and normalized to cotransfected b-galactosidase activity (n ¼ 8). (B) The mRNA levels of ABCA1 were measured in primary hepatocytes treated with 1 mM T0901317 and
10 mg/mL PPT using qRT-PCR (n ¼ 4). (C) The protein levels of ABCA1 were determined in the presence or absence of T0901317 and/or PPT using immunoblot analysis. (D) ChIP
assays were performed using anti-RNA polymerase II or IgG antibodies after the treatment of primary hepatocytes with 1 mM T0901317 and 10 mg/mL PPT (n ¼ 4). Levels of
immunoprecipitated LXRE-containing DNA were determined by qRT-PCR and normalized to input DNA. Data are presented as means ± SD. DMSO, dimethyl sulfoxide; T1317,
T0901317. **, P < 0.01 vs. DMSO; ***, P < 0.001 vs. DMSO.
G.-S. Oh et al. / Journal of Pharmacological Sciences 128 (2015) 71e77 75the expression levels of SREBP-1c and ABCA1, even though both
SREBP-1c and ABCA1 have LXREs in their promoters and are well-
known LXRa target genes.
3.5. Recruitment of the coactivator TRAP80 to the SREBP-1c
promoter can be inhibited by PPT
Recently, TRAP80 was reported to be a lipogenic coactivator in
hepatocytes (25). TRAP80 is selectively recruited to the SREBP-1c
promoter, but not the ABCA1 promoter. Herein, we investigated
whether PPT has any effect on the recruitment of TRAP80 to theFig. 5. Recruitment of the lipogenic coactivator TRAP80 to the LXRE regions of SREBP-1c (A)
mL PPT, ChIP assays were performed using anti-TRAP80 or IgG antibodies (n ¼ 4). Levels of i
by qRT-PCR and normalized to input DNA. Data are presented as means ± SD. DMSO, dimeSREBP-1c promoter using ChIP assay. Surprisingly, PPT inhibited
the T0901317-dependent recruitment of TRAP80 to the LXRE
region of the endogenous SREBP-1c promoter (Fig. 5A). By
contrast, TRAP80 was not recruited to ABCA1 LXRE regardless of
the presence or absence of T0901317 and/or PPT in primary
mouse hepatocytes (Fig. 5B). Consistent with the ChIP assay,
the interaction between LXRa and TRAP80 was shown to be
inhibited by PPT by mammalian two hybrid system (Fig. 6A).
Furthermore, TRAP80 overexpression derepressed the PPT-
mediated inhibition of SREBP-1c promoter activity and tran-
script level (Fig. 6: B and C).and ABCA1 (B). After treatment of primary hepatocytes with 1 mM T0901317 and 10 mg/
mmunoprecipitated SREBP-1c LXRE- or ABCA1 LXRE-containing DNA were determined
thyl sulfoxide; T1317, T0901317. *, P < 0.05 vs. DMSO; ##, P < 0.01 vs. T1317.
Fig. 6. Derepression of inhibitory PPT effects on T0901317-dependent activation of SREBP-1c by TRAP80 overexpression. (A) Mammalian two hybrid assay was performed between
Gal4-TRAP80 and VP16-hLXRa LBD in the presence or absence of PPT using a Gal4-TK-luciferase assay (n ¼ 9). Luciferase activity was normalized to cotransfected b-galactosidase
activity. (B, C) The effects of TRAP80 overexpression on the inhibition of (B) SREBP-1c promoter activity (n ¼ 6) and (C) SREBP-1c transcript levels (n ¼ 3) by PPT. Increasing amounts
of TRAP80 cDNA (50, 100, and 200 ng DNA) were transfected into HepG2 cells and primary hepatocytes for each experiment (B) and (C), respectively. Data are presented as
means ± SD. DMSO, dimethyl sulfoxide; T1317, T0901317. **, P < 0.01 vs. DMSO; ***, P < 0.001 vs. DMSO; #, P < 0.05 vs. T1317; ##, P < 0.01 vs. T1317; ###, P < 0.001 vs. T1317.
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Our current study aimed to identify phytochemicals with anti-
lipogenic activity from P. ginseng by screening for Gal4-LXRa
inhibitors. Excessive hepatic lipogenesis is one of the major path-
ogenic pathways in the development of non-alcoholic fatty liver
disease (NAFLD). Fat accumulation in hepatocytes is caused by
increased fatty acid uptake, increased de novo lipogenesis, impaired
fatty acid oxidation, and reduced secretion of very low density
lipoprotein (26). Among these pathogenic pathways, de novo lipo-
genesis reportedly contributes to ~26% of the hepatic fat accumu-
lation in NAFLD patients, whereas fatty acid uptake by diet only
contributes to ~15% (27). There is currently no satisfactory agent to
control excess lipogenesis for the treatment of NAFLD. Herein, we
show that PPT reduces LXRa-mediated fat accumulation in primary
hepatocytes.
PPT is an aglycone of the PPT-type ginsenosides, which include
the ginsenosides Re, Rf, Rg1, Rg2, and Rh1. The ginsenoside Re has
been reported to inhibit the transcription of SREBP-1c through the
activation of AMP-activated protein kinase in HepG2 cells (28).
Gu et al. showed that the ginsenoside Rh1, another PPT-type gin-
senoside, reduces the expression of PPARg, CCAAT/enhancer-
binding proteina, FAS, and adipocyte fatty acidebinding protein,
and inhibits adipocyte differentiation in 3T3-L1 cells (14). However,
to date, no study of ginsenosides related to LXRa-mediated lipo-
genesis has been reported. Herein, the ginsenoside Rh1 was found
to exert inhibitory activity against the autonomous transactivation
of LXRa, but could not signiﬁcantly inhibit LXRa-mediated tran-
scription of SREBP-1c. Importantly, aglycone PPT signiﬁcantly
inhibited both the autonomous transactivation of LXRa and LXRa-
stimulated transcription of SREBP-1c. Notably, PPD, an aglycone of
the PPD-type ginsenosides, did not inhibit LXRa-related activities.
Recently, Zhang et al. reported that PPT is a novel PPARg
antagonist that can inhibit rosiglitazone-enhanced adipocyte dif-
ferentiation of 3T3-L1 cells by repressing the expression of
lipogenesis-related genes (29). They also showed that PPT allevi-
ated steatosis and improved serum lipid proﬁle in high-fat diet-
induced obesity mice and ob/ob mice (29). In that same study, the
authors reported that PPT did not inhibit LXRa transactivation, but
they did not present LXRa-related data. They employed a Gal4-UAS
system in HEK293T cells to test the effects of PPT on the trans-
activation of several nuclear hormone receptors, including PPARa,PPARg, and PPARd. Whereas we used the Gal4-UAS system in
HepG2 hepatoma cells to determine the effect of PPT on LXRa
transactivation. We then conﬁrmed the effects of PPT using quan-
titative RT-PCR analysis of LXRa target gene expression levels, a
ChIP assay for RNA polymerase II, and measurements of cellular
lipid accumulation in primary mouse hepatocytes.
Interestingly, we found that PPT can inhibit the recruitment of
TRAP80 to the LXRE region of the SREBP-1c promoter. TRAP80 was
previously identiﬁed as an LXRa- interacting protein using HepG2
nuclear extracts with GST-LXRa LBD as bait (25). TRAP80 can
stimulate the transcription of lipogenic genes, including SREBP-1c,
but does not affect the transcription of RCT-related genes, such as
ABCA1 (25). This selective activity of TRAP80 is consistent with the
differential effects of PPT on the transcription of SREBP-1c and
ABCA1. PPT inhibited the LXRa-dependent transcription of SREBP-
1c, but not ABCA1. RCT can act to help maintain low levels of
LDL-cholesterol. Furthermore, it has been established that PPT re-
duces the recruitment of TRAP80 to the LXRE of the SREBP-1c gene.
These ﬁndings suggest that TRAP80 could potentially be used as a
target protein for the development of anti-lipogenic therapeutic
agents, such as PPT.
In conclusion, we ﬁnd that PPT has inhibitory activity against
LXRa-mediated lipogenesis in primary mouse hepatocytes by
repressing the recruitment of RNA polymerase II and TRAP80 to the
LXRE of the SREBP-1c gene. Our present ﬁndings suggest that PPT
could represent a potential anti-lipogenic agent for treating NAFLD.Conﬂicts of interest
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